Yale Drug use, Addiction and HIV Research Scholars (DAHRS)

7.项目总结/摘要 耶鲁大学药物使用，成瘾和艾滋病毒研究学者计划（DAHRS）始于2013年，其目的是 培养一批来自多个医学专业的多样化的年轻教师，以满足发展一个 一个训练有素的临床学者库，进行与药物相关的生物医学，行为和临床研究 使用，成瘾，艾滋病毒预防和治疗在一般医疗环境。药物使用患者 疾病通常在一般医疗环境中接受医疗护理， 部门;艾滋病毒，青少年和妇女健康和其他专业诊所;呈现出复杂的阵列 物质的急性后果和并发症（如中毒、过量、戒断和创伤） 使用和慢性疾病，如疼痛，艾滋病毒疾病，肝炎，肺和心脏疾病。患者 越来越多地出现在这些环境中，用于预防和治疗成瘾本身。耶鲁大学-DAHRS 该计划提供了一个全面的三年博士后，跨学科的指导职业发展 该计划结合了强大的教学研究课程，导致健康科学硕士学位 学位，指导研究和与成瘾医学相关的主题培训：[目标1]培养临床医生 科学家的知识，技能和能力，成为独立的调查人员，产生的结果， 对改善吸毒、成瘾和有吸毒风险的患者的健康具有重大影响的实用价值， HIV; [目标2]通过为学者提供领导技能和创建个性化的 计划，以确保成功地领导多学科研究团队在研究药物使用，成瘾和 艾滋病毒，以及将研究成果落实和纳入一般医疗环境;以及[目标3] 加强药物使用、成瘾和艾滋病毒研究人员的多样性。支持妇女的职业生涯， 代表性不足的少数民族教师增强了研究人员和研究课题的多样性，扩大了 在确定研究优先事项的角度，增加临床试验的参与，并扩大知识。到 迄今为止，我们的计划已经证明成功利用现有培训和临床 耶鲁大学和我们的社区合作伙伴的课程，以及我们经验丰富，多元化的团队提供的经验， 跨学科核心教师、导师和咨询委员会。我们招收了五名学者（四名女性） 来自内科、儿科、急诊、妇产科和肺科等领域的 药所有三名毕业生都接受了学术研究职位。一个获得了独立的NIDA R 01资助，是两个NIH资助赠款的共同研究者;一个从两个 机构NIH赠款，正在等待R21 NIH审查;第三个是NIDA和CDC的共同研究者 正在等待两项赠款的审查。所有人都在高影响力的期刊和教科书上发表过文章， 临床专业的新兴领导者。这是第一次更新支持四名学者，受益于 我们为改进项目所做的反复修改，增加了下一代的研究人员。

7. Project Summary/Abstract The Yale-Drug use, Addiction and HIV Research Scholar program (DAHRS) began in 2013 with the aim of training a group of diverse young faculty from multiple medical specialties to meet the critical need to develop a pool of highly trained clinician scholars to conduct biomedical, behavioral and clinical research related to drug use, addiction, and HIV prevention and treatment in general medical settings. Patients with substance use disorders often receive medical care in general medical settings such as primary care clinics and emergency departments; HIV, adolescent and women's health and other specialty clinics; presenting with a complex array of acute consequences and complications (e.g. intoxication, overdose, withdrawal, and trauma) of substance use and chronic conditions such as pain, HIV disease, hepatitis, pulmonary and cardiac disease. Patients are increasingly presenting to these settings for the prevention and treatment of addiction itself. The Yale-DAHRS program provides a comprehensive three year post-doctorate, interdisciplinary Mentored Career Development Program that incorporates a robust didactic research curriculum leading to a Masters in Health Science degree, mentored research and training in topics related to Addiction Medicine to: [Aim 1] Develop clinician scientists with the knowledge, skills, and ability to become independent investigators, generating findings of practical value with significant impact to improve health in patients with and at risk for drug use, addiction, and HIV; [Aim 2] Develop future leaders by providing Scholars with leadership skills and creating individualized programs to ensure success in leading multidisciplinary research teams in studying drug use, addiction and HIV, and implementation and integration of research findings into general medical settings; and [Aim 3] Enhance the diversity of drug use, addiction, and HIV researchers. Supporting the careers of women and under-represented minority faculty enhances the diversity of investigators and research topics, broadens perspectives in setting research priorities, increases clinical trial participation, and expands knowledge. To date, our program has demonstrated success capitalizing on the synergies of established training and clinical programs at Yale and our community partners, and the experiences offered by our seasoned, diverse group of interdisciplinary core faculty, mentors and advisory committee. We have enrolled five Scholars (four women) from the fields of internal medicine, pediatrics, emergency medicine, obstetrics and gynecology and pulmonary medicine. All three graduates accepted academic research positions. One has received independent NIDA R01 funding and is co-investigator on two NIH funded grants; one received PI pilot funding from two institutional NIH grants and is awaiting an R21 NIH review; the third is a co-investigator on NIDA and CDC grants and is awaiting review on two grants. All have published in high impact journals and textbooks and are emerging leaders in their clinical specialties. This first time renewal supports four Scholars, benefiting from the iterative changes we have made to improve the program, adding to the next generation of investigators.